Cellulitishttps://ht.wikipedia.org/wiki/Celluitis
Cellulitis se yon enfeksyon bakteri ki enplike kouch ki pi fon po a. Kòm siy ak sentòm, gen yon zòn douloure ki vin wouj epi ki ogmante an gwosè sou kèk jou. Fwontyè zòn wouj la souvan pa byen defini, epi po a ka anfle. Zòn enfeksyon an anjeneral douloure. Moun nan ka gen lafyèv ak myalgia.

Janm yo ak figi a se kote ki pi souvan afekte. Faktè risk yo enkli obezite, anfle janm, ak vyeyès. Bakteri ki pi souvan enplike yo se streptokok ak Staphylococcus aureus.

Tretman an anjeneral fèt ak antibyotik oral, tankou cephalexin, amoxicillin oswa cloxacillin. Anviwon 95 % moun yo santi amelyorasyon apre 7 a 10 jou de tretman. Moun ki gen dyabèt, sepandan, souvan gen rezilta pi move.

Selulit se yon maladi komen; nan Wayòm Ini a, li te koze 1.6 % admisyon lopital. Nan 2015, selulit te lakoz apeprè 16 900 lanmò atravè lemond.

Tretman – Medikaman OTC
Selulit ki avanse mande antibyotik ki preskri sèlman pa yon doktè. Si blesi a pwogrese rapidman epi li akonpaye pa lafyèv ak frison, li rekòmande pou w wè yon doktè pi vit posib.
Aplike yon krèm antibyotik ki pa bezwen preskripsyon sou blesi a ka ede. Si krèm lan aplike twò mens, li ka pa efikas ditou.
#Polysporin
#Bacitracin
#Betadine

Sèvi ak medikaman ki soulaje doulè san preskripsyon, tankou asetaminofèn, pou kalme doulè a.
#Ibuprofen
#Naproxen
#Acetaminophen

Kenbe pye yo pwòp epi trete pye atlèt la, paske li ogmante risk pou selulit.

Tretman
#First‑generation cephalosporins (e.g. Cefradine)
#Bacterial culture
#Third‑generation cephalosporins (e.g. Cefditoren Pivoxil)
☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
  • Janm lan se yon kote komen pou Cellulitis.
  • Kisa tipik?
  • Cellulitis — etap gerizon
  • Selulit sou janm gòch la. Si li gaye anpil, li ka koze gwo lafyèv ki mennen nan chòk septik ki menase lavi.
  • Lè blesi a ap amelyore, ipèpigmantasyon pòs-enflamatwa ka parèt.
  • Li ka koze pa yon blesi sou palmis la.
  • Kisa tipik?
  • Si yon plak eritematoz sansib gaye rapidman, yo ta dwe sispèk cellulitis.
  • Kòm Cellulitis amelyore, selil po ki mouri yo ka dekale, epi li ka vin grate.
  • Pifò ka cellulitis akonpaye pa anfle ak eritem nan zòn ki antoure a. Sepandan, nan ka eksepsyonèl kote pa gen okenn eritem ki antoure, yo ta dwe sispèk kansè selil squamous tou.
  • Ka tipik.
  • Fè gerizon.
References Cellulitis 31747177 
NIH
Cellulitis se yon enfeksyon bakteri po ki komen. Li afekte plis pase 14 milyon moun chak ane Ozetazini. Li koze apeprè 3.7 milya dola depans swen sante epi 650,000 admisyon lopital chak ane. Anjeneral, cellulitis parèt kòm yon zòn cho, wouj sou po a, anfle, epi ki sansib. Li rive lè yon bakteri antre toudenkou epi deklanche enflamasyon nan kouch po ki fon ak tisi ki toupre. Pa gen okenn absè oswa pi gwo enfeksyon ki asosye ak li. Beta-emolitik streptococcus, espesyalman gwoup A streptococcus (Streptococcus pyogenes), se kòz ki pi souvan, ki swiv pa methicillin-sensitive Staphylococcus aureus.
Cellulitis is a common bacterial skin infection, with over 14 million cases occurring in the United States annually. It accounts for approximately 3.7 billion dollars in ambulatory care costs and 650000 hospitalizations annually. Cellulitis typically presents as a poorly demarcated, warm, erythematous area with associated edema and tenderness to palpation. It is an acute bacterial infection causing inflammation of the deep dermis and surrounding subcutaneous tissue. The infection is without an abscess or purulent discharge. Beta-hemolytic streptococci typically cause cellulitis, generally group A streptococcus (i.e., Streptococcus pyogenes), followed by methicillin-sensitive Staphylococcus aureus. Patients who are immunocompromised, colonized with methicillin-resistant Staphylococcus aureus, bitten by animals, or have comorbidities such as diabetes mellitus may become infected with other bacteria.
 Cellulitis: current insights into pathophysiology and clinical management 29219814
Cellulitis se yon enfeksyon bakteri ki afekte po a ak tisi mou yo. Li rive lè gen pwoblèm ak baryè pwoteksyon po a, sistèm iminitè a, oswa sikilasyon san. Dyabèt, obezite, ak vyeyès ogmante risk pou cellulitis lè yo afekte zòn sa yo. Nou gade tou dènye rezilta yo sou dyagnostik cellulitis, mete aksan sou enpòtans dyagnostik egzat paske kondisyon tankou ensifizans venn, ekzema, tronboz venn gwo twou san fon, ak gout souvan konfonn ak selulit. Antibyotik yo itilize pou trete cellulitis chwazi ak anpil atansyon pou vize bakteri komen san yo pa ankouraje rezistans antibyotik. Nou pale tou de nouvo antibyotik ki apwouve pou cellulitis. Cellulitis souvan tounen akòz faktè risk kontinyèl ak domaj nan sistèm lenfatik la.
Cellulitis is a bacterial infection of the skin and soft tissues. It happens when there are issues with the skin's protective barrier, the immune system, or blood circulation. Diabetes, obesity, and old age increase the chances of cellulitis by affecting these areas. We also look at recent findings on diagnosing cellulitis, highlighting the importance of accurate diagnosis since conditions like venous insufficiency, eczema, deep vein thrombosis, and gout are often confused with cellulitis. Antibiotics used to treat cellulitis are chosen carefully to target common bacteria without encouraging antibiotic resistance. We also talk about new antibiotics approved for cellulitis. Cellulitis often comes back because of ongoing risk factors and damage to the lymphatic system..
 Current Treatment Options for Acute Skin and Skin-structure Infections 30957166 
NIH
Anpil moun ale nan lopital oswa sal dijans pou enfeksyon bakteri sou po ki parèt toudenkou. Staphylococcus aureus se jèm prensipal ki lakòz enfeksyon sa yo, epi li vin pi difisil pou trete paske gen kèk souch ki reziste kont antibyotik komen.
Acute bacterial skin and skin-structure infections are a common reason for seeking care at acute healthcare facilities, including emergency departments. Staphylococcus aureus is the most common organism associated with these infections, and the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) has represented a considerable challenge in their treatment.
 Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus 32257966 
NIH
Staphylococcus aureus ka divize an de kalite selon repons li bay antibyotik: methicillin-sensitive Staphylococcus aureus (MSSA) ak methicillin-resistant Staphylococcus aureus (MRSA). Pandan kèk deseni ki sot pase yo, akòz evolisyon bakteri a ak twòp itilizasyon antibyotik, rezistans S. Aureus kont antibyotik yo te ogmante, sa ki mennen nan yon ogmantasyon mondyal nan enfeksyon MRSA.
According to the sensitivity to antibiotic drugs, S. aureus can be divided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). In recent decades, due to the evolution of bacteria and the abuse of antibiotics, the drug resistance of S. aureus has gradually increased, the infection rate of MRSA has increased worldwide.
 Treatment of severe skin and soft tissue infections: a review 29278528 
NIH
To review the salient features of the management of severe skin and soft tissue infections (SSTIs), including toxic shock syndrome, myonecrosis/gas gangrene, and necrotizing fasciitis.